质量水平
检测方案
≥98% (HPLC)
形式
powder
颜色
white
溶解性
DMSO: 9 mg/mL
创始人
Novartis
储存温度
−20°C
SMILES字符串
NC(=O)c1cn(Cc2c(F)cccc2F)nn1
InChI
1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
InChI key
POGQSBRIGCQNEG-UHFFFAOYSA-N
基因信息
human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
正在寻找类似产品? 访问 产品对比指南
应用
Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.
生化/生理作用
Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.
特点和优势
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
诊断含义
Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.
警示用语：
Warning
危险声明
危险分类
Carc. 2 - Repr. 2 - STOT SE 3
靶器官
Central nervous system
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
M Häusler et al.
Neuropediatrics, 42(1), 28-29 (2011-05-11)
Epilepsy with myoclonic absences (EMA) is a rare epileptic syndrome with frequently poor response to antiepileptic treatment. Rufinamide (RUF) is a relatively new EMEA- and FDA-approved anticonvulsant licensed as an orphan drug for the adjunctive treatment of patients with Lennox-Gastaut
Shin Hye Kim et al.
Seizure, 21(4), 288-291 (2012-03-17)
To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included
Iolanda Mazzucchelli et al.
Analytical and bioanalytical chemistry, 401(3), 1013-1021 (2011-06-07)
The development of a simple and rapid high-performance liquid chromatography (HPLC) method for the determination of the new antiepileptic drug rufinamide (RFN) in human plasma and saliva is reported. Samples (250 μl) are alkalinized with ammonium hydroxide (pH 9.25) and
K K Jain
Expert opinion on investigational drugs, 9(4), 829-840 (2000-11-04)
This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12
Shahin Hakimian et al.
Expert opinion on pharmacotherapy, 8(12), 1931-1940 (2007-08-19)
Rufinamide (1-[2,6-difluorobenzyl]-1H-1,2,3-triazole-4-carboxamide) is a new anti-epileptic drug with a novel triazole derivative structure. The suspected mechanism of action is limitation of sodium-dependent action potentials, thought to result in a membrane stabilizing effect. Rufinamide is extensively metabolized in the liver by
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门